BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 32611686)

  • 1. Identification of FABP5 as an immunometabolic marker in human hepatocellular carcinoma.
    Liu F; Liu W; Zhou S; Yang C; Tian M; Jia G; Wang H; Zhu B; Feng M; Lu Y; Qiao T; Wang X; Cao W; Wang X; Shi Y; Wu D
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32611686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterogeneity of exhausted T cells in the tumor microenvironment is linked to patient survival following resection in hepatocellular carcinoma.
    Liu F; Liu W; Sanin DE; Jia G; Tian M; Wang H; Zhu B; Lu Y; Qiao T; Wang X; Shi Y; Wu D
    Oncoimmunology; 2020; 9(1):1746573. PubMed ID: 32426177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fatty acid-binding protein 5 function in hepatocellular carcinoma through induction of epithelial-mesenchymal transition.
    Ohata T; Yokoo H; Kamiyama T; Fukai M; Aiyama T; Hatanaka Y; Hatanaka K; Wakayama K; Orimo T; Kakisaka T; Kobayashi N; Matsuno Y; Taketomi A
    Cancer Med; 2017 May; 6(5):1049-1061. PubMed ID: 28374947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fatty acid binding protein 5 promotes tumor angiogenesis and activates the IL6/STAT3/VEGFA pathway in hepatocellular carcinoma.
    Pan L; Xiao H; Liao R; Chen Q; Peng C; Zhang Y; Mu T; Wu Z
    Biomed Pharmacother; 2018 Oct; 106():68-76. PubMed ID: 29957468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum fatty acid-binding protein 5 is a significant factor in hepatocellular carcinoma progression independent of tissue expression level.
    Ohira M; Yokoo H; Ogawa K; Fukai M; Kamiyama T; Sakamoto N; Taketomi A
    Carcinogenesis; 2021 Jun; 42(6):794-803. PubMed ID: 33754641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma.
    Barsch M; Salié H; Schlaak AE; Zhang Z; Hess M; Mayer LS; Tauber C; Otto-Mora P; Ohtani T; Nilsson T; Wischer L; Winkler F; Manne S; Rech A; Schmitt-Graeff A; Bronsert P; Hofmann M; Neumann-Haefelin C; Boettler T; Fichtner-Feigl S; van Boemmel F; Berg T; Rimassa L; Di Tommaso L; Saeed A; D'Alessio A; Pinato DJ; Bettinger D; Binder H; John Wherry E; Schultheiss M; Thimme R; Bengsch B
    J Hepatol; 2022 Aug; 77(2):397-409. PubMed ID: 35367533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD1
    Ma J; Zheng B; Goswami S; Meng L; Zhang D; Cao C; Li T; Zhu F; Ma L; Zhang Z; Zhang S; Duan M; Chen Q; Gao Q; Zhang X
    J Immunother Cancer; 2019 Nov; 7(1):331. PubMed ID: 31783783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Study of abnormal lipid metabolism analysis and significance of fatty acid binding protein expression in patients with hepatocellular carcinoma].
    Lin YX; Chen K; An FM; Wang YF; Wu XB; Zhan Q; Zhang GQ
    Zhonghua Gan Zang Bing Za Zhi; 2021 Oct; 29(10):1006-1013. PubMed ID: 34814397
    [No Abstract]   [Full Text] [Related]  

  • 9. Survival of tissue-resident memory T cells requires exogenous lipid uptake and metabolism.
    Pan Y; Tian T; Park CO; Lofftus SY; Mei S; Liu X; Luo C; O'Malley JT; Gehad A; Teague JE; Divito SJ; Fuhlbrigge R; Puigserver P; Krueger JG; Hotamisligil GS; Clark RA; Kupper TS
    Nature; 2017 Mar; 543(7644):252-256. PubMed ID: 28219080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC.
    Gabrielson A; Wu Y; Wang H; Jiang J; Kallakury B; Gatalica Z; Reddy S; Kleiner D; Fishbein T; Johnson L; Island E; Satoskar R; Banovac F; Jha R; Kachhela J; Feng P; Zhang T; Tesfaye A; Prins P; Loffredo C; Marshall J; Weiner L; Atkins M; He AR
    Cancer Immunol Res; 2016 May; 4(5):419-30. PubMed ID: 26968206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of downregulation of liver fatty acid-binding protein in hepatocellular carcinoma.
    Inoue M; Takahashi Y; Fujii T; Kitagawa M; Fukusato T
    World J Gastroenterol; 2014 Dec; 20(46):17541-51. PubMed ID: 25516669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritic cell infiltration and prognosis of human hepatocellular carcinoma.
    Cai XY; Gao Q; Qiu SJ; Ye SL; Wu ZQ; Fan J; Tang ZY
    J Cancer Res Clin Oncol; 2006 May; 132(5):293-301. PubMed ID: 16421755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Canopy Homolog 2 Expression Predicts Poor Prognosis in Hepatocellular Carcinoma with Tumor Hemorrhage.
    Wang D; Wang ZM; Zhang S; Wu HJ; Tao YM
    Cell Physiol Biochem; 2018; 50(6):2017-2028. PubMed ID: 30415246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishment and validation of exhausted CD8+ T cell feature as a prognostic model of HCC.
    Shi J; Li G; Liu L; Yuan X; Wang Y; Gong M; Li C; Ge X; Lu S
    Front Immunol; 2023; 14():1166052. PubMed ID: 37077914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FABP4 suppresses proliferation and invasion of hepatocellular carcinoma cells and predicts a poor prognosis for hepatocellular carcinoma.
    Zhong CQ; Zhang XP; Ma N; Zhang EB; Li JJ; Jiang YB; Gao YZ; Yuan YM; Lan SQ; Xie D; Cheng SQ
    Cancer Med; 2018 Jun; 7(6):2629-2640. PubMed ID: 29733540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fatty-acid-induced FABP5/HIF-1 reprograms lipid metabolism and enhances the proliferation of liver cancer cells.
    Seo J; Jeong DW; Park JW; Lee KW; Fukuda J; Chun YS
    Commun Biol; 2020 Oct; 3(1):638. PubMed ID: 33128030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma.
    Calderaro J; Petitprez F; Becht E; Laurent A; Hirsch TZ; Rousseau B; Luciani A; Amaddeo G; Derman J; Charpy C; Zucman-Rossi J; Fridman WH; Sautès-Fridman C
    J Hepatol; 2019 Jan; 70(1):58-65. PubMed ID: 30213589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fatty acid binding protein 5 suppression attenuates obesity-induced hepatocellular carcinoma by promoting ferroptosis and intratumoral immune rewiring.
    Sun J; Esplugues E; Bort A; Cardelo MP; Ruz-Maldonado I; Fernández-Tussy P; Wong C; Wang H; Ojima I; Kaczocha M; Perry R; Suárez Y; Fernández-Hernando C
    Nat Metab; 2024 Apr; 6(4):741-763. PubMed ID: 38664583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 4-1BB Delineates Distinct Activation Status of Exhausted Tumor-Infiltrating CD8
    Kim HD; Park S; Jeong S; Lee YJ; Lee H; Kim CG; Kim KH; Hong SM; Lee JY; Kim S; Kim HK; Min BS; Chang JH; Ju YS; Shin EC; Song GW; Hwang S; Park SH
    Hepatology; 2020 Mar; 71(3):955-971. PubMed ID: 31353502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver-infiltrating CD8(+) lymphocytes as prognostic factor for tumour recurrence in hepatitis C virus-related hepatocellular carcinoma.
    Ramzan M; Sturm N; Decaens T; Bioulac-Sage P; Bancel B; Merle P; Tran Van Nhieu J; Slama R; Letoublon C; Zarski JP; Jouvin-Marche E; Marche PN; Leroy V
    Liver Int; 2016 Mar; 36(3):434-44. PubMed ID: 26215124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.